InsidersTradesSigma
Vanda Pharmaceuticals Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Vanda Pharmaceuticals Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vanda Pharmaceuticals Inc. has recorded 118 reports. Market capitalisation: €377.7m. The latest transaction was reported on 21 May 2025 (Acquisition). Among the most active insiders: Polymeropoulos Mihael Hristos. All data is accessible without an account.
118
Insider Decl.
0
Thresholds
€324,029
9 ops.
Buy Volume
€2m
35 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vanda Pharmaceuticals Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$14.90.
43Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 21,519 of 25,936 companies
28.4
score / 100
Value6
Quality51
FCF yld-28%
Earn yld-56%
EV/EBITDA·
ROE-60%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 21 May 2025
Declarations118 total
9,519 shares@ US$4.401.9% of flowCommon StockSEC:0000950170-25-076012:0
Ideal exit: 15 Feb 2026 (T+270)
20,000 shares@ US$4.22364.0% of flowCommon StockSEC:0000950170-25-074565:0
Ideal exit: 10 Feb 2026 (T+270)
5,000 shares@ US$5.021.2% of flowCommon StockSEC:0000950170-25-034966:0
Ideal exit: 1 Dec 2025 (T+270)
5,000 shares@ US$5.011.2% of flowCommon StockSEC:0000950170-25-033845:0
Ideal exit: 30 Nov 2025 (T+270)
26,941 shares@ US$4.7658.4% of flowCommon StockSEC:0000950170-25-032281:0
95,999 shares@ US$4.7623.1% of flowCommon StockSEC:0000950170-25-032276:0
26,941 shares@ US$4.7625.3% of flowCommon StockSEC:0000950170-25-032270:0
15,520 shares@ US$4.7623.7% of flowCommon StockSEC:0000950170-25-032285:0
26,941 shares@ US$4.7629.1% of flowCommon StockSEC:0000950170-25-032273:0
10,000 shares@ US$4.762.4% of flowCommon StockSEC:0000950170-25-030176:0
Ideal exit: 25 Nov 2025 (T+270)
10,000 shares@ US$4.762.4% of flowCommon StockSEC:0000950170-25-029059:0
Ideal exit: 24 Nov 2025 (T+270)
5,000 shares@ US$4.751.2% of flowCommon StockSEC:0000950170-25-027860:0
Ideal exit: 23 Nov 2025 (T+270)
10,000 shares@ US$4.4642.2% of flowCommon StockSEC:0000950170-25-027056:0
Ideal exit: 22 Nov 2025 (T+270)
2,000 shares@ US$4.38942.0% of flowCommon StockSEC:0000950170-25-025914:0
Ideal exit: 18 Nov 2025 (T+270)
125,000 shares0Common StockSEC:0000950170-25-024487:0
125,000 shares0Common StockSEC:0000950170-25-024486:0
125,000 shares0Common StockSEC:0000950170-25-024485:0
125,000 shares0Common StockSEC:0000950170-25-024498:0
450,000 shares0Common StockSEC:0000950170-25-024489:0
5,000 shares@ US$5.17269.3% of flowCommon StockSEC:0000950170-24-128115:0
2,251 shares@ US$5.92032.9% of flowCommon StockSEC:0000950170-24-087381:0
21,887 shares0Common StockSEC:0000950170-24-064669:0
20,529 shares0Common StockSEC:0000950170-24-063015:0
20,529 shares0Common StockSEC:0000950170-24-063017:0
20,529 shares0Common StockSEC:0000950170-24-063022:0
25 of 118 declarations
About Vanda Pharmaceuticals Inc.
From a competitive standpoint, Vanda operates in highly contested specialty markets where differentiation depends on clinical efficacy, safety profile, intellectual property protection, and commercial execution. The company focuses on niche therapeutic areas rather than mass markets, which can support attractive margins if launches succeed, but also increases binary risk tied to FDA decisions and clinical trial outcomes. Recent 2026 public updates highlighted regulatory progress around imsidolimab and the commercial launch of NEREUS in the United States, while also indicating that certain HETLIOZ-related regulatory requests faced unfavorable outcomes. For investors, Vanda therefore looks like a healthcare name with a high risk/reward profile, highly sensitive to FDA catalysts, Fanapt sales momentum, and the company’s ability to translate its pipeline into recurring revenue.
